Effects of Combination Therapy in Postmenopausal Breast Cancer
Author Information
Author(s): M. Dowsett, A.L. Harris, I.E. Smith, S.L. Jeffcoate
Primary Institution: Chelsea Hospital for Women and Royal Marsden Hospital
Hypothesis
Does combining tamoxifen, aminoglutethimide, and hydrocortisone provide a clinical benefit over individual treatments in postmenopausal breast cancer patients?
Conclusion
The combination therapy showed no clinical benefit compared to individual treatments despite endocrine changes.
Supporting Evidence
- Combination therapy did not improve response rates compared to individual treatments.
- Endocrine changes were observed but did not correlate with clinical benefits.
- Non-responders had higher levels of certain hormones compared to responders.
Takeaway
Doctors tried mixing three medicines to help women with breast cancer, but it didn't work better than using just one or two of them.
Methodology
Patients were treated with tamoxifen, aminoglutethimide, and hydrocortisone, and hormone levels were measured before and during treatment.
Limitations
The study did not find significant clinical benefits from the combination therapy, which may limit its applicability.
Participant Demographics
All participants were postmenopausal women with advanced breast cancer who had not received previous endocrine therapy.
Statistical Information
P-Value
P=0.004 for oestrone levels between responders and non-responders.
Want to read the original?
Access the complete publication on the publisher's website